Cyrus Tang Hematology Center, Jiangsu Institute of Hematology, First Affiliated Hospital, Soochow University, 199 Ren Ai Road, Suzhou 215123, China.
Trends Endocrinol Metab. 2013 Jun;24(6):310-9. doi: 10.1016/j.tem.2013.03.004. Epub 2013 Apr 27.
Skeletal muscle loss due to aging, motor-neuron degeneration, cancer, heart failure, and ischemia is a serious condition for which currently there is no effective treatment. Insulin-like growth factor 1 (IGF-I) plays an important role in muscle maintenance and repair. Preclinical studies have shown that IGF-I is involved in increasing muscle mass and strength, reducing degeneration, inhibiting the prolonged and excessive inflammatory process due to toxin injury, and increasing the proliferation potential of satellite cells. However, clinical trials have not been successful due to ineffective delivery methods. Choosing the appropriate isoforms or peptides and developing targeted delivery techniques can resolve this issue. Here we discuss the latest development in the field with special emphasis on novel therapeutic approaches.
由于衰老、运动神经元退化、癌症、心力衰竭和缺血导致的骨骼肌丧失是一种严重的疾病,目前尚无有效的治疗方法。胰岛素样生长因子 1(IGF-1)在肌肉维持和修复中发挥着重要作用。临床前研究表明,IGF-1 可增加肌肉质量和力量,减少退化,抑制因毒素损伤引起的长期和过度的炎症过程,并增加卫星细胞的增殖潜力。然而,由于无效的给药方法,临床试验并未成功。选择合适的同工型或肽并开发靶向递送技术可以解决这个问题。本文特别强调新的治疗方法,讨论了该领域的最新进展。